Novo Nordisk has plans to acquire Inversago Pharma, a developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders. The 1.075-billion-dollar acquisition includes Inversago Pharma’s lead development asset INV-202, an oral CB1 inverse agonist.
Read on